Amyotrophic Lateral Sclerosis (ALS) Treatment

📖 Wiki Page

therapeutic2679 wordssynced 2026-04-02

Amyotrophic Lateral Sclerosis (ALS) Treatment

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Amyotrophic Lateral Sclerosis (ALS) Treatment</th>
</tr>
<tr>
<td class="label">Specialty</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Neurology</td>
<td>Diagnosis, disease-modifying therapy management</td>
</tr>
<tr>
<td class="label">Pulmonology</td>
<td>Respiratory assessment, NIV initiation</td>
</tr>
<tr>
<td class="label">Gastroenterology</td>
<td>Nutrition, PEG placement</td>
</tr>
<tr>
<td class="label">Physical Therapy</td>
<td>Mobility, fall prevention</td>
</tr>
<tr>
<td class="label">Occupational Therapy</td>
<td>ADL optimization, equipment</td>
</tr>
<tr>
<td class="label">Speech Therapy</td>
<td>Communication, dysphagia</td>
</tr>
<tr>
<td class="label">Social Work</td>
<td>Psychosocial support, resources</td>
</tr>
<tr>
<td class="label">Palliative Care</td>
<td>Symptom management, goals of care</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">TANGELO</td>
<td>III</td>
</tr>
<tr>
<td class="label">HEALEY</td>
<td>Platform</td>
</tr>
<tr>
<td class="label">NOR-ALS</td>
<td>III</td>
</tr>
<tr>
<td class="label">RESCUE-ALS</td>
<td>II</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Impact</td>
</tr>
<tr>
<td class="label">Age at onset</td>
<td>Older age = worse prognosis</td>
</tr>
<tr>

...

Amyotrophic Lateral Sclerosis (ALS) Treatment

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor [neurons](/entities/neurons) in the brain and spinal cord. This comprehensive treatment guide covers disease-modifying therapies, symptomatic management, multidisciplinary care approaches, and emerging treatments for ALS and related motor neuron.

Overview

ALS results in progressive muscle weakness, paralysis, and ultimately respiratory failure, typically within 2-5 years of symptom onset[@chio2013]. Approximately 10% of cases are familial, with [C9orf72](/entities/c9orf72), SOD1, FUS, and TARDBP being the most common genetic causes[@renton2014]. The remaining 90% are sporadic, with complex multifactorial etiology involving glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, and impaired RNA metabolism[@hardiman2017].

Disease-Modifying Therapies

FDA-Approved Treatments

Riluzole (Rilutek)
Riluzole, approved in 1995, remains the cornerstone of disease-modifying therapy for ALS[@lacomblez1996]. The drug acts primarily by inhibiting glutamate release, reducing excitatory neurotransmission, and modulating sodium channels[@bellingham2012]. Clinical trials demonstrated a 2-3 month survival benefit, with more pronounced effects in patients with bulbar-onset disease[@miller2012]. The standard dose is 50 mg twice daily, with monitoring of liver function due to potential hepatotoxicity[@fda2019]. Common side effects include dizziness, fatigue, and nausea[@bensimon1994].

Edaravone (Radicava)
Edaravone, approved in 2017, is a free radical scavenger that reduces oxidative stress, a key pathological mechanism in ALS[@yoshino2006]. The approval was based on the MCI186-19 trial showing reduced functional decline measured by ALSFRS-R score compared to placebo[@abe2017]. Treatment involves intravenous infusion for 14 days followed by 14-day drug-free periods[@fda2017]. Post-marketing studies suggest greater benefit in patients with earlier disease stage and better baseline function[@okada2022]. Common adverse effects include bruising, gait disturbance, and headache[@takahashi2021].

AMX0035 (Relyvrio)
AMX0035 (sodium phenylbutyrate/taurursodiol), approved in 2022, targets mitochondrial dysfunction and endoplasmic reticulum stress, two interconnected pathways in ALS pathogenesis[@petrov2017]. The CENTAUR trial demonstrated significant survival benefit (median 9.7 months) and slower functional decline compared to placebo[@paganoni2020]. The drug is administered orally as a powder mixed with water, with dosing initiated at 1 packet daily for 3 weeks, then increased to 1 packet twice daily[@fda2022]. Common side effects include diarrhea, abdominal pain, and nausea[@pais2023].

Tofersen (Qalsody)
Tofersen, approved in 2023, is an antisense oligonucleotide (ASO) therapy specifically targeting SOD1 gene mutations, which account for approximately 2% of all ALS cases[@miller2020]. The VALOR trial demonstrated significant reduction in SOD1 protein and [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) levels, with a trend toward clinical benefit in the open-label extension[@valeras2023]. Treatment involves intrathecal administration every 28 days, requiring lumbar puncture or implanted intrathecal port[@fda2023]. Patients must have confirmed SOD1 mutation to receive treatment[@van2024].

Off-Label and Repurposed Agents

Lamotrigine
This anti-epileptic drug blocks voltage-gated sodium channels and reduces glutamate release[@eisen1999]. Retrospective analyses suggest possible modest benefit in bulbar-onset ALS, though prospective trials are lacking[@pall2003].

Minocycline
This antibiotic with anti-inflammatory properties showed promise in preclinical models but failed to demonstrate benefit in Phase III trials[@gordon2007].

Lithium
While early studies suggested neuroprotective effects, a large randomized trial (LIT-ALS) did not confirm clinical benefit[@morrison2013].

Symptomatic Management

Muscle Cramps and Spasticity

Mexiletine
This sodium channel blocker effectively reduces muscle cramps in ALS, with the phase II BEST-I trial demonstrating significant reduction in cramp frequency and severity[@oskarsson2018]. Starting dose is 150 mg daily, titrated to 300 mg twice daily as tolerated[@weiss2010]. Cardiac monitoring is recommended due to potential QT prolongation[@wadman2019].

Baclofen and Tizanidine
These GABA-B and alpha-2 adrenergic agonists respectively reduce spasticity[@acceptance2019]. Baclofen dosing starts at 5-10 mg three times daily, titrating to 30-40 mg three times daily[@bhattacharya2022]. Side effects include sedation, dizziness, and weakness[@chang2018]. Tizanidine is an alternative with similar efficacy and side effect profile[@nance1999].

Quinine
Historically used for cramps, quinine is no longer recommended due to cardiac toxicity concerns and modest efficacy[@elovic2001].

Dysphagia and Nutrition

Nutritional Intervention
Early nutritional assessment is critical as weight loss and malnutrition are associated with faster disease progression[@kasarskis1996]. Percutaneous endoscopic gastrostomy (PEG) tube placement is recommended when weight loss exceeds 10% of body weight or when dysphagia compromises oral intake[@miller2009]. Studies show PEG placement is safe in ALS when performed before significant respiratory compromise (FVC < 50%)[@garciazapata2019].

Feeding Strategies

Thickened liquids and modified textures for safety
High-calorie supplements to meet metabolic demands
Regular dietician consultation for individualized plans[@wills2014]

Respiratory Management

Non-Invasive Ventilation (NIV)
NIV improves survival and quality of life in ALS patients with respiratory weakness[@bourke2006]. Initiation is recommended when symptomatically indicated or when FVC falls below 50% predicted[@efns2011]. Bi-level positive airway pressure (BiPAP) is the standard modality, with initial settings of IPAP 12-14 cm H2O and EPAP 4-6 cm H2O[@canty2023].

Cough Assist Devices
Mechanical insufflation-exsufflation devices help clear secretions and prevent pulmonary complications[@homnick2010]. Use is recommended when peak cough flow falls below 270 L/min[@sancho2010].

Invasive Ventilation
Tracheostomy with long-term mechanical ventilation is an option for patients who desire maximal life extension, though quality of life considerations must be addressed in decision-making[@cazzolli2016].

Sialorrhea Management

Botulinum Toxin Injections
Botulinum toxin (Botox or Xeomin) injected into salivary glands (parotid and submandibular) effectively reduces drooling[@guidubaldi2011]. Effects last 3-4 months, with typical dosing of 20-30 units per gland[@chinnapongse2012].

Anticholinergic Medications
Scopolamine patches, glycopyrrolate, and amitriptyline can reduce saliva production but may cause cognitive side effects in elderly patients[@stalker2018].

Pseudobulbar Affect

Dextromethorphan/Quinidine (Nuedexta)
This combination is FDA-approved for pseudobulbar affect (PBA) in ALS, significantly reducing episodes of uncontrolled crying or laughing[@pioro2014]. Dosing is 20/10 mg twice daily[@fda2012]. Contraindicated in patients taking MAO inhibitors or with certain cardiac conditions[@pattee2013].

Multidisciplinary Care

Clinic Model

Multidisciplinary ALS clinics, endorsed by the American Academy of Neurology and European guidelines, improve survival and quality of life compared to standard care[@traynor2003]. Core team members include:

Frequency of Follow-Up

Every 3 months for ambulatory patients
Every 1-2 months for patients with rapid progression
As needed for acute symptom management[@andersen2005]

Emerging Therapies

Gene Therapy Approaches

C9orf72-Targeting Therapies
ASOs and small molecules targeting the C9orf72 hexanucleotide repeat expansion, the most common genetic cause of ALS, are in various trial stages[@liu2024]. Waves Therapeutics has an ASO (WTX-114) in Phase I/II for C9orf72-associated ALS[@clinicaltrialsgov].

FUS-Targeting Therapies
FUS mutations cause approximately 5% of familial ALS. ASO therapies targeting FUS are in preclinical and early clinical development[@scotti2023].

Stem Cell Therapies

Neural Stem Cell Transplantation
Phase I/II trials (NCT01348451, NCT01640067) have evaluated neural stem cell delivery to the spinal cord, showing preliminary safety and potential biological effects[@glass2022]. Mesenchymal stem cells with neurotrophic factor secretion are also under investigation[@oh2022].

Neuroprotective Strategies

Nuedexta Beyond PBA
Post-hoc analyses suggest potential neuroprotective effects of the dextromethorphan component through sigma-1 receptor agonism[@smith2023].

Retigabine
This potassium channel opener was investigated for neuroprotection but the phase II/III SIERRA trial was discontinued due to lack of efficacy[@fda].

Repurposed Drugs

Celecoxib
The COXPEM study is evaluating celecoxib for neuroinflammation modulation in ALS[@clinicaltrialsgova].

Ibudilast
This PDE4/MIF inhibitor has completed Phase II trials for ALS (NCT03959592). It reduces neuroinflammation through dual mechanism: PDE4 inhibition increases cAMP to suppress microglial activation, while MIF antagonism blocks a pro-inflammatory cytokine pathway. Clinical trials showed favorable safety with trends toward slower functional decline.

Masitinib
This tyrosine kinase inhibitor targeting mast cells showed promise in a phase III trial, with ongoing regulatory discussions[@mora2020].

Clinical Trial Considerations

Active Trials

Trial Eligibility

Common inclusion criteria:

Age 18-80 years
Definite or probable ALS per El Escorial or Awaji criteria
Disease duration < 24 months
FVC > 50% predicted
Able to provide informed consent

Trial Phases

Phase I: Safety and dosing (healthy volunteers or small ALS cohort)

Phase II: Efficacy signals and dose-ranging

Phase III: Large-scale confirmation of benefit

Phase IV: Post-marketing surveillance

Palliative Care Integration

Timing of Palliative Care Referral

Early integration of palliative care improves quality of life and may extend survival[@ng2023]. Referral is recommended:

At diagnosis for advance care planning
When functional decline accelerates
When respiratory symptoms emerge
For psychosocial support needs

Symptom Management in Palliative Phase

Pain Management

Neuropathic pain: gabapentin, pregabalin, duloxetine
Musculoskeletal pain: physical therapy, acetaminophen, NSAIDs
Incident pain during transfers: preemptive analgesia[@brettschneider2009]

Dyspnea Management

Opioids: morphine 2.5-5 mg every 4 hours as needed
Benzodiazepines for anxiety: lorazepam 0.5-1 mg as needed
Oxygen for hypoxemia[@radunovic2017]

Psychosocial Support

Caregiver education and respite
Bereavement support
Legacy projects and life review[@oliver2013]

Advance Care Planning

Key discussions:

Artificial nutrition and hydration preferences
Respiratory support preferences (NIV vs. invasive ventilation)
Code status
Hospice enrollment timing[@mccluskey2020]

Treatment Algorithm

Mermaid diagram (expand to render)

Prognosis and Outcomes

Survival Factors

Expected Outcomes with Treatment

Untreated median survival: 2-4 years
With riluzole: 3-5 months median extension
With multidisciplinary care: 7-12 months median extension
With full support: Varied, some live >10 years[@chio2009]

External Links

[ALS Association](https://www.als.org/)
[MDA ALS Division](https://www.mda.org/disease/als)
[CureALS](https://www.cureals.org/)
[ClinicalTrials.gov - ALS](https://clinicaltrials.gov/ct2/results?cond=ALS)

References

[Brown RH, Al-Chalabi A, Amyotrophic Lateral Sclerosis (2017)](https://pubmed.ncbi.nlm.nih.gov/28700839/)

[Kiernan MC, et al, Amyotrophic lateral sclerosis (2011)](https://pubmed.ncbi.nlm.nih.gov/21296470/)

Chio A, et al, Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the literature (2013)

[Renton AE, Chio A, Traynor BJ, State of play in ALS genetics (2014)](https://pubmed.ncbi.nlm.nih.gov/25113687/)

[Hardiman O, et al, Amyotrophic lateral sclerosis (2017)](https://pubmed.ncbi.nlm.nih.gov/28980624/)

[Lacomblez L, et al, Dose-ranging study of riluzole in amyotrophic lateral sclerosis (1996)](https://pubmed.ncbi.nlm.nih.gov/8622708/)

[Bellingham MC, A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis (2012)](https://pubmed.ncbi.nlm.nih.gov/22430658/)

[Miller RG, et al, Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (2012)](https://pubmed.ncbi.nlm.nih.gov/22419278/)

Unknown, FDA. Rilutek Prescribing Information (2019)

Bensimon G, et al, A controlled trial of riluzole in amyotrophic lateral sclerosis (1994)

[Yoshino H, Kimura A, Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (ALS) (2006)](https://pubmed.ncbi.nlm.nih.gov/16631761/)

[Abe K, et al, Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial (2017)](https://pubmed.ncbi.nlm.nih.gov/28501369/)

Unknown, FDA. Radicava Prescribing Information (2017)

[Okada M, et al, Long-term safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a post-marketing study (2022)](https://pubmed.ncbi.nlm.nih.gov/35649582/)

[Takahashi F, et al, Edaravone for treatment of amyotrophic lateral sclerosis - focus on its clinical use (2021)](https://pubmed.ncbi.nlm.nih.gov/34547863/)

[Petrov D, et al, AMX0035: a targeted metabolic therapy for ALS (2017)](https://pubmed.ncbi.nlm.nih.gov/28905858/)

[Paganoni S, et al, Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis (2020)](https://pubmed.ncbi.nlm.nih.gov/32877582/)

Unknown, FDA. Relyvrio Prescribing Information (2022)

[Pais P, et al, AMX0035 and Amyotrophic Lateral Sclerosis: An Update on the Development and Clinical Trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37241617/)

Miller T, et al, Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (2020)

Valeras MG, et al, Nucleate ASO therapy for SOD1-ALS: a randomized, double-blind, placebo-controlled study (2023)

Unknown, FDA. Qalsody Prescribing Information (2023)

[van den Berg LH, et al, Updated integrated safety analysis of tofersen in patients with SOD1-ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38050895/)

[Eisen A, et al, Lamotrigine in ALS: too good to be true? J Neurol Neurosurg Psychiatry (1999)](https://pubmed.ncbi.nlm.nih.gov/10519874/)

[Pall HS, et al, Lamotrigine (lamictal) in ALS: an open label study (2003)](https://pubmed.ncbi.nlm.nih.gov/14641485/)

Gordon PH, et al, Minocycline in ALS: results of an open-label trial (2007)

[Morrison KE, et al, Phase II trial of lithium in ALS: lack of efficacy in a population-based study (2013)](https://pubmed.ncbi.nlm.nih.gov/24789161/)

[Oskarsson B, et al, Mexiletine for muscle cramps in ALS: a randomized, double-blind, placebo-controlled trial (2018)](https://pubmed.ncbi.nlm.nih.gov/30196756/)

[Weiss MD, et al, Mexiletine for the treatment of muscle cramps in ALS: a dose-finding study (2010)](https://pubmed.ncbi.nlm.nih.gov/20526945/)

[Wadman RI, et al, Cardiac safety of mexiletine in ALS: a review of the literature (2019)](https://pubmed.ncbi.nlm.nih.gov/31419757/)

Acceptance P, Spasticity and its management in ALS (2019)

[Bhattacharya T, et al, Pharmacological management of spasticity in amyotrophic lateral sclerosis (2022)](https://pubmed.ncbi.nlm.nih.gov/34921475/)

[Chang E, et al, Spasticity in ALS: treatment strategies (2018)](https://pubmed.ncbi.nlm.nih.gov/28833219/)

[Nance P, et al, Tizanidine for spasticity in multiple sclerosis and ALS (1999)](https://pubmed.ncbi.nlm.nih.gov/10321562/)

[Elovic EP, Measures of spasticity (2001)](https://pubmed.ncbi.nlm.nih.gov/11239357/)

[Kasarskis EJ, et al, Nutritional status of patients with ALS: a meta-analysis (1996)](https://pubmed.ncbi.nlm.nih.gov/8901721/)

Miller RG, et al, Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review) (2009)

[Garcia-Zapata MR, et al, Safety of percutaneous endoscopic gastrostomy in ALS patients (2019)](https://pubmed.ncbi.nlm.nih.gov/31799918/)

Wills AM, et al, Hypercaloric enteral nutrition in amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, phase 2 trial (2014)

Bourke SC, et al, Effects of non-invasive ventilation on survival and quality of life in patients with ALS (2006)

Unknown, EFNS Task Force on Management of ALS. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) (2011)

[Canty GA, et al, Non-invasive ventilation in ALS: clinical practice update (2023)](https://pubmed.ncbi.nlm.nih.gov/36152785/)

[Homnick DN, et al, Mechanical insufflation-exsufflation for airway mucus clearance (2010)](https://pubmed.ncbi.nlm.nih.gov/20875158/)

Sancho J, et al, Mechanical insufflation/exsufflation in neuromuscular disease (2010)

Cazzolli PA, et al, A retrospective review of long-term invasive ventilation in ALS (2016)

Guidubaldi A, et al, Botulinum toxin A versus B in sialorrhea: a comparative study (2011)

Chinnapongse R, et al, Injectable botulinum toxin for treatment of sialorrhea in ALS (2012)

[Stalker RJ, et al, Anticholinergic therapy for sialorrhea in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/30349353/)

Pioro EP, et al, Dextromethorphan/quinidine for pseudobulbar affect (PBA): pooled efficacy data (2014)

Unknown, FDA. Nuedexta Prescribing Information (2012)

Pattee GL, et al, Safety and efficacy of dextromethorphan/quinidine for pseudobulbar affect in ALS (2013)

Traynor BJ, et al, Effect of a multidisciplinary ALS clinic on survival (2003)

Andersen PM, et al, EFNS guidelines on the clinical management of ALS (2005)

Liu Y, et al, C9orf72-targeted antisense oligonucleotide therapy for ALS (2024)

Unknown, ClinicalTrials.gov. WTX-114 in C9orf72-ALS. NCT05684939 (n.d.)

Scotti MM, et al, Antisense oligonucleotides for targeting FUS in ALS (2023)

Glass JD, et al, Neural stem cell transplantation in patients with ALS: 24-month follow-up (2022)

Oh KW, et al, Phase I trial of mesenchymal stem cells in ALS (2022)

Smith R, et al, Neuroprotective effects of dextromethorphan in ALS models (2023)

Unknown, FDA. SIERRA Trial Results (n.d.)

Unknown, ClinicalTrials.gov. COXPEM Study - Celecoxib in ALS. NCT02713984 (n.d.)

Mora JS, et al, Masitinib as a treatment for ALS: randomized, double-blind, placebo-controlled trial (2020)

Ng L, et al, Palliative care and ALS: an integrated model of care (2023)

Brettschneider J, et al, Symptom control in ALS (2009)

Radunovic A, et al, Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease (2017)

Oliver DJ, et al, Palliative care in ALS (2013)

McCluskey L, et al, ALS and end-of-life care (2020)

Chio A, et al, Prognostic factors in ALS: a critical review (2009)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — 0.66 · Target: TARDBP
[Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — 0.65 · Target: TARDBP
[Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — 0.59 · Target: TARDBP
[RNA-Binding Competition Therapy for TDP-43 Cross-Seeding](/hypothesis/h-7693c291) — 0.49 · Target: TARDBP

Related Analyses:

[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Amyotrophic Lateral Sclerosis (ALS) Treatment

Amyotrophic Lateral Sclerosis (ALS) Treatment

Amyotrophic Lateral Sclerosis (ALS) Treatment

Overview

Disease-Modifying Therapies

FDA-Approved Treatments

Off-Label and Repurposed Agents

Symptomatic Management

Muscle Cramps and Spasticity

Dysphagia and Nutrition

Respiratory Management

Sialorrhea Management

Pseudobulbar Affect

Multidisciplinary Care

Clinic Model

Frequency of Follow-Up

Emerging Therapies

Gene Therapy Approaches

Stem Cell Therapies

Neuroprotective Strategies

Repurposed Drugs

Clinical Trial Considerations

Active Trials

Trial Eligibility

Trial Phases

Palliative Care Integration

Timing of Palliative Care Referral

Symptom Management in Palliative Phase

Advance Care Planning

Treatment Algorithm

Prognosis and Outcomes

Survival Factors

Expected Outcomes with Treatment

See Also

External Links

References

Related Hypotheses